Keikawus Arastéh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Keikawus Arastéh has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
M L'Age
4 shared publicationsW Heise
4 shared publicationsG Grosse
3 shared publications- Viviana Simon
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 shared publications C Cordes
2 shared publicationsC Schneider
2 shared publications
Latest Publications
- 19 September 2003
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 128 (38) , 1957-1962
Screening und Therapie der analen intraepithelialen Neoplasie (AIN) und des Analkarzinoms bei HIV-Infektion
Die anale intraepitheliale Neoplasie (AIN) ist ein möglicher Vorläufer des invasiven Analkarzinoms. Seit Einführung der hochaktiven antiretroviralen Therapie (HAART) ist es, nicht zuletzt durch eine signifikante Senkung der Mortalität und Morbidität und damit verlängerter Überlebenszeit zu einem Anstieg der Inzidenz des Analkarzinoms bei HIV-Infizierten gekommen. Die Inzidenz des Analkarzinoms bei homosexuellen Männern ist mit einer Rate von ca. 35/100 000 im Vergleich zur Allgemeinbevölkerung deutlich erhöht. Diese Inzidenz entspricht in etwa der Inzidenz des Cervixkarzinoms vor Einführung der zytologischen Vorsorgeuntersuchung. Sowohl beim Analkarzinom als auch beim Cervixkarzinom existieren, neben der Assoziation zum humanen Papillomvirus (HPV-Infektion), mögliche Krebsvorstufen: die anale intraepitheliale Neoplasie (AIN) und zervikale intraepitheliale Neoplasie (CIN). Seit der Etablierung der derzeitigen Screeningmethoden für CIN und anschließender Therapie ist es zu einer deutlichen Senkung der Inzidenz des Cervixkarzinoms gekommen. Trotz des erhöhten Analkarzinom-Risikos bei HIV-Infizierten, insbesondere bei Hochrisikopersonen, existiert bisher kein etabliertes Screeningprotokoll wie beim Cervixkarzinom. Ein Screeningprotokoll könnte helfen, durch Früherkennung die Inzidenz des Analkarzinoms bei HIV-Infizierten zu senken und damit auch Ressourcen im Gesundheitssystem einzusparen. Anal intraepithelial neoplasia (AIN) is a potential precursor of invasive anal carcinoma. Introduction of highly active antiretroviral therapy (HAART) in the treatment of HIV infection substantially reduced the incidence of some diseases associated with opportunistic viral infections. However, the incidence of AIN is reported to increase and HAART seems to have only little impact on the regression or progression of AIN. Paradoxically, improvement of survival in the HAART era results in an increased risk of anal cancer. The incidence of anal carcinoma amongst homosexual men is substantially higher compared to the normal population (35/100.000). This incidence is similar to the incidence of cervical cancer before screening for CIN with cervical cytology. Recent data suggest that the incidence of AIN and anal cancer is even higher among HIV-infected individuals. Both cancer entities share biologic similarities, including the association with human papillomavirus infection (HPV). Screening for CIN with cervical cytology and early treatment has resulted in a significant decline in the incidence of cervical carcinoma. Like cervical cancer, anal carcinoma may be preventable through identification and treatment of its precursors. Future efforts should focus on a screening protocol, training of clinicians in the diagnosis and treatment of AIN and anal carcinoma, and novel approaches to treatment of these lesions. This screening protocol could help to reduce anal cancer in HIV-infection as well as save limited resources in health care system.
- 19 September 2003
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 128 (38) , 1957-1962
Screening und Therapie der analen intraepithelialen Neoplasie (AIN) und des Analkarzinoms bei HIV-Infektion
Die anale intraepitheliale Neoplasie (AIN) ist ein möglicher Vorläufer des invasiven Analkarzinoms. Seit Einführung der hochaktiven antiretroviralen Therapie (HAART) ist es, nicht zuletzt durch eine signifikante Senkung der Mortalität und Morbidität und damit verlängerter Überlebenszeit zu einem Anstieg der Inzidenz des Analkarzinoms bei HIV-Infizierten gekommen. Die Inzidenz des Analkarzinoms bei homosexuellen Männern ist mit einer Rate von ca. 35/100 000 im Vergleich zur Allgemeinbevölkerung deutlich erhöht. Diese Inzidenz entspricht in etwa der Inzidenz des Cervixkarzinoms vor Einführung der zytologischen Vorsorgeuntersuchung. Sowohl beim Analkarzinom als auch beim Cervixkarzinom existieren, neben der Assoziation zum humanen Papillomvirus (HPV-Infektion), mögliche Krebsvorstufen: die anale intraepitheliale Neoplasie (AIN) und zervikale intraepitheliale Neoplasie (CIN). Seit der Etablierung der derzeitigen Screeningmethoden für CIN und anschließender Therapie ist es zu einer deutlichen Senkung der Inzidenz des Cervixkarzinoms gekommen. Trotz des erhöhten Analkarzinom-Risikos bei HIV-Infizierten, insbesondere bei Hochrisikopersonen, existiert bisher kein etabliertes Screeningprotokoll wie beim Cervixkarzinom. Ein Screeningprotokoll könnte helfen, durch Früherkennung die Inzidenz des Analkarzinoms bei HIV-Infizierten zu senken und damit auch Ressourcen im Gesundheitssystem einzusparen. Anal intraepithelial neoplasia (AIN) is a potential precursor of invasive anal carcinoma. Introduction of highly active antiretroviral therapy (HAART) in the treatment of HIV infection substantially reduced the incidence of some diseases associated with opportunistic viral infections. However, the incidence of AIN is reported to increase and HAART seems to have only little impact on the regression or progression of AIN. Paradoxically, improvement of survival in the HAART era results in an increased risk of anal cancer. The incidence of anal carcinoma amongst homosexual men is substantially higher compared to the normal population (35/100.000). This incidence is similar to the incidence of cervical cancer before screening for CIN with cervical cytology. Recent data suggest that the incidence of AIN and anal cancer is even higher among HIV-infected individuals. Both cancer entities share biologic similarities, including the association with human papillomavirus infection (HPV). Screening for CIN with cervical cytology and early treatment has resulted in a significant decline in the incidence of cervical carcinoma. Like cervical cancer, anal carcinoma may be preventable through identification and treatment of its precursors. Future efforts should focus on a screening protocol, training of clinicians in the diagnosis and treatment of AIN and anal carcinoma, and novel approaches to treatment of these lesions. This screening protocol could help to reduce anal cancer in HIV-infection as well as save limited resources in health care system.
- 30 August 2002
- Vol. 7 (8) , 341-6
Predictors of treatment failure during highly active antiretroviral therapy (racing trial).
To determine factors associated with virological failure during long-term treatment with the triple combination of saquinavir soft gel capsule, zalcitabine and zidovudine. Open-label, prospective, multicentre study undertaken in private practices and the outpatient department of the Auguste-Viktoria-Hospital. A total of 95 patients with plasma HIV RNA > 5000 copies/ml who had received no more than 6 months pre-treatment with NRTIs and no prior PI therapy received saquinavir soft gel, zalcitabine and zidovudine for 52 weeks, before being randomly assigned to either remain on therapy or switch to nelfinavir, lamivudine and zidovudine for further 52 weeks. Combination therapy with saquinavir, zalcitabine and zidovudine was found to be effective and well tolerated, with virological response to therapy maintained for up to 2 years. In patients responding to therapy, switching to a novel triple regimen did not result in a virological or immunological worsening, but it did not confer an additional clinical benefit. Factors predictive of early treatment failure (virological failure within 16 weeks of treatment initiation) included high viral load and presence of RT mutations at baseline (OR: 0.30, 95% CI 0.11 0.83 and OR 0.13, 95% CI 0.03 0.52, respectively), with baseline viral load and the development of genotypic mutations on therapy being predictive of late treatment failure (16 52 weeks; OR: 0.15, 95% 0.05 0.46 and OR: 0.26, 95% CI < 0.001 1.16, respectively). Plasma saquinavir concentration < 50 mg/ml at 4 weeks was also found to be an independent risk factor for both early and late treatment failure (OR: 1.80, 95% CI 1.23 2.64 and OR: 1.16, 95% CI 0.84 1.60, respectively). While antiretroviral drug resistance appears to be a principal cause of treatment failure, other factors such as inadequate drug plasma concentrations also play a role.
- 30 August 2002
- Vol. 7 (8) , 341-6
Predictors of treatment failure during highly active antiretroviral therapy (racing trial).
To determine factors associated with virological failure during long-term treatment with the triple combination of saquinavir soft gel capsule, zalcitabine and zidovudine. Open-label, prospective, multicentre study undertaken in private practices and the outpatient department of the Auguste-Viktoria-Hospital. A total of 95 patients with plasma HIV RNA > 5000 copies/ml who had received no more than 6 months pre-treatment with NRTIs and no prior PI therapy received saquinavir soft gel, zalcitabine and zidovudine for 52 weeks, before being randomly assigned to either remain on therapy or switch to nelfinavir, lamivudine and zidovudine for further 52 weeks. Combination therapy with saquinavir, zalcitabine and zidovudine was found to be effective and well tolerated, with virological response to therapy maintained for up to 2 years. In patients responding to therapy, switching to a novel triple regimen did not result in a virological or immunological worsening, but it did not confer an additional clinical benefit. Factors predictive of early treatment failure (virological failure within 16 weeks of treatment initiation) included high viral load and presence of RT mutations at baseline (OR: 0.30, 95% CI 0.11 0.83 and OR 0.13, 95% CI 0.03 0.52, respectively), with baseline viral load and the development of genotypic mutations on therapy being predictive of late treatment failure (16 52 weeks; OR: 0.15, 95% 0.05 0.46 and OR: 0.26, 95% CI < 0.001 1.16, respectively). Plasma saquinavir concentration < 50 mg/ml at 4 weeks was also found to be an independent risk factor for both early and late treatment failure (OR: 1.80, 95% CI 1.23 2.64 and OR: 1.16, 95% CI 0.84 1.60, respectively). While antiretroviral drug resistance appears to be a principal cause of treatment failure, other factors such as inadequate drug plasma concentrations also play a role.
- 9 April 2002
- p. 66-70
[Improving resistance profile, simplifying administration mode. New antiretroviral drugs].
We had some good news in the last year: Tenofovir received its FDA approval, a new class of antiretrovirals, the fusion-inhibitors, entered phase III trials and there are some promising agents in the pipeline of the pharmaceutical laboratories. The major issue in the development of new drugs is the antiretroviral activity. One of the "winners" here is TMC-125, a new NNRTI. But people focus also on the side-effects of the HAART, especially on long-term toxicity. One example is Atazanavir, a protease inhibitor which doesn't show any increase in cholesterin or triglycerides. But all the exciting news drugs have to prove their real potential in large phase III trials.
- 9 April 2002
- p. 66-70
[Improving resistance profile, simplifying administration mode. New antiretroviral drugs].
We had some good news in the last year: Tenofovir received its FDA approval, a new class of antiretrovirals, the fusion-inhibitors, entered phase III trials and there are some promising agents in the pipeline of the pharmaceutical laboratories. The major issue in the development of new drugs is the antiretroviral activity. One of the "winners" here is TMC-125, a new NNRTI. But people focus also on the side-effects of the HAART, especially on long-term toxicity. One example is Atazanavir, a protease inhibitor which doesn't show any increase in cholesterin or triglycerides. But all the exciting news drugs have to prove their real potential in large phase III trials.
- 1 August 2001
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 2 (4) , 307-316
GW420867X Administered to HIV-1-Infected Patients Alone and in Combination with Lamivudine and Zidovudine
Purpose: GW420867X is a nonnucleoside inhibitor of HIV-1 reverse transcriptase. The primary objective was to assess the safety of GW420867X in HIV-1-infected patients. The secondary objectives were to assess the effect of GW420867X on plasma HIV-1 RNA and viral genotype and phenotype and to examine the pharmacokinetics of GW420867X in HIV-1-infected patients. Method: HIV-1-infected patients were randomized to GW420867X 50 mg/day, 100 mg/day, or 200 mg/day from days 1-28 (n = 15 per group). Lamivudine (3TC) plus zidovudine (ZDV) was added from days 8-28. A control group (n = 15) received GW420867X, 3TC, and ZDV placebos. Results: Plasma HIV-1 RNA and CD4+ counts improved in the GW420867X groups at days 8 and 28. No significant development of drug resistance was detected. Median observed peak GW420867X concentration (Cmax) generally occurred at 2 hours. The area under the curve over the dosing interval (AUCτ)on day 14 increased less than proportionally to dose, suggesting there was increased clearance and/or decreased absorption. Mean trough GW420867X concentrations were many fold above the in vitro IC50 in the presence of human serum proteins. Seven of 15 patients on 50 mg GW420867X, 8/15 on 100 mg GW420867X, 12/15 on 200 mg GW420867X, and 8/15 on placebo reported drug-related adverse events. Conclusion: GW420867X was well tolerated and has potent antiretroviral activity alone and in combination with 3TC plus ZDV.
- 1 August 2001
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 2 (4) , 307-316
GW420867X Administered to HIV-1-Infected Patients Alone and in Combination with Lamivudine and Zidovudine
Purpose: GW420867X is a nonnucleoside inhibitor of HIV-1 reverse transcriptase. The primary objective was to assess the safety of GW420867X in HIV-1-infected patients. The secondary objectives were to assess the effect of GW420867X on plasma HIV-1 RNA and viral genotype and phenotype and to examine the pharmacokinetics of GW420867X in HIV-1-infected patients. Method: HIV-1-infected patients were randomized to GW420867X 50 mg/day, 100 mg/day, or 200 mg/day from days 1-28 (n = 15 per group). Lamivudine (3TC) plus zidovudine (ZDV) was added from days 8-28. A control group (n = 15) received GW420867X, 3TC, and ZDV placebos. Results: Plasma HIV-1 RNA and CD4+ counts improved in the GW420867X groups at days 8 and 28. No significant development of drug resistance was detected. Median observed peak GW420867X concentration (Cmax) generally occurred at 2 hours. The area under the curve over the dosing interval (AUCτ)on day 14 increased less than proportionally to dose, suggesting there was increased clearance and/or decreased absorption. Mean trough GW420867X concentrations were many fold above the in vitro IC50 in the presence of human serum proteins. Seven of 15 patients on 50 mg GW420867X, 8/15 on 100 mg GW420867X, 12/15 on 200 mg GW420867X, and 8/15 on placebo reported drug-related adverse events. Conclusion: GW420867X was well tolerated and has potent antiretroviral activity alone and in combination with 3TC plus ZDV.
- 2 April 2001
- p. 14-7
[New antiretroviral drugs. Improved pharmacokinetics and simpler dose schedules].
Despite of 18 licensed antiretroviral drugs in Germany, there is an increased pressure for development of new substances and new targets in the treatment of HIV positive patients. Multidrug resistance and poor pharmacokinetics are the biggest problems we have to fight with. But there is hope for resolving these challenges. Second generation drugs like FTC and DPC 083 with once a day dosage and a high resistance barrier are tested in clinical trials. In addition new classes of HIV drugs are available in phase III trials (T-20 fusion inhibitor). So the future will provide us with some new effective arms in the battle against HIV.
- 2 April 2001
- p. 14-7
[New antiretroviral drugs. Improved pharmacokinetics and simpler dose schedules].
Despite of 18 licensed antiretroviral drugs in Germany, there is an increased pressure for development of new substances and new targets in the treatment of HIV positive patients. Multidrug resistance and poor pharmacokinetics are the biggest problems we have to fight with. But there is hope for resolving these challenges. Second generation drugs like FTC and DPC 083 with once a day dosage and a high resistance barrier are tested in clinical trials. In addition new classes of HIV drugs are available in phase III trials (T-20 fusion inhibitor). So the future will provide us with some new effective arms in the battle against HIV.
- 30 October 2000
- Vol. 5 (10) , 424-30
HIV-related nontuberculous mycobacterial infection: incidence, survival analysis and associated risk factors.
To evaluate the incidence and survival time for AIDS-patients affected by different stages of nontuberculous mycobacterial (NTM) infection we performed a retrospective study. Data of 1540 hospitalised AIDS-patients was analyzed with respect to survival time and incidence rates. The overall incidence rate of NTM following AIDS was 16.6/100 person-years (PY), with an increase from 12.1/100PY (1987-1990) to 18.9/100PY (1991-1994). Antiretroviral therapy (ART) and toxoplasmosis prophylaxis reduced the risk of NTM disease whereas CD4 cells <40/ microl at time of the first AIDS defining illness led to a 2.5 fold higher risk. Pneumocystis carinii pneumonia (PCP), wasting syndrome and PCP prophylaxis increased the risk of progression from colonization to dissemination. Cryptococcus neoformans infection, wasting syndrome, PCP prophylaxis and CD4 cells <40/ microl were linked to immediate NTM dissemination. Though the incidence of NTM dissemination increased by the factor 1.56 in 1991-1994, survival did not differ between patients with and without NTM infection.
- 30 October 2000
- Vol. 5 (10) , 424-30
HIV-related nontuberculous mycobacterial infection: incidence, survival analysis and associated risk factors.
To evaluate the incidence and survival time for AIDS-patients affected by different stages of nontuberculous mycobacterial (NTM) infection we performed a retrospective study. Data of 1540 hospitalised AIDS-patients was analyzed with respect to survival time and incidence rates. The overall incidence rate of NTM following AIDS was 16.6/100 person-years (PY), with an increase from 12.1/100PY (1987-1990) to 18.9/100PY (1991-1994). Antiretroviral therapy (ART) and toxoplasmosis prophylaxis reduced the risk of NTM disease whereas CD4 cells <40/ microl at time of the first AIDS defining illness led to a 2.5 fold higher risk. Pneumocystis carinii pneumonia (PCP), wasting syndrome and PCP prophylaxis increased the risk of progression from colonization to dissemination. Cryptococcus neoformans infection, wasting syndrome, PCP prophylaxis and CD4 cells <40/ microl were linked to immediate NTM dissemination. Though the incidence of NTM dissemination increased by the factor 1.56 in 1991-1994, survival did not differ between patients with and without NTM infection.
- 1 April 2000
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 5 (90001) , 28-31
The Role of Vascular Endothelial Growth Factor (VEGF) in AIDS-Related Kaposi's Sarcoma
Kaposi's sarcoma (KS) is the most common neoplasm associated with human immunodeficiency virus-1 (HIV-1) infection. KS involves the skin and mucous membranes as well as other organs and can lead to tumor-associated edema and ulcerations. Despite therapy with highly active antiviral agents, most patients with HIV-1-related KS eventually develop disseminated disease. In the treatment of KS, a strong rationale exists for the use of agents that inhibit vascular endothelial growth factor (VEGF). Angiogenesis appears to be an important feature of this disease, and recent experimental studies have demonstrated the role of VEGF and its receptors in the pathogenesis of KS. Thus, therapeutic agents that target the VEGF pathway may be an effective strategy in reducing the tumor growth and edema associated with KS. Phase I study results with SU5416, a synthetic low molecular-weight inhibitor of the VEGF-Flk-1/KDR receptor tyrosine kinase, demonstrate that this agent is well tolerated. Preliminary results show that in a majority of patients with autoimmune deficiency syndrome (AIDS)-related disease, SU5416 clearly has biological activity (it flattens, shrinks, or dissolves lesions and reduces or resolves edema) or stabilizes the disease. Angiogenesis inhibition with SU5416 is a promising therapeutic approach in treating patients with KS, and further clinical evaluation is currently under way.
- 1 April 2000
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 5 (90001) , 28-31
The Role of Vascular Endothelial Growth Factor (VEGF) in AIDS-Related Kaposi's Sarcoma
Kaposi's sarcoma (KS) is the most common neoplasm associated with human immunodeficiency virus-1 (HIV-1) infection. KS involves the skin and mucous membranes as well as other organs and can lead to tumor-associated edema and ulcerations. Despite therapy with highly active antiviral agents, most patients with HIV-1-related KS eventually develop disseminated disease. In the treatment of KS, a strong rationale exists for the use of agents that inhibit vascular endothelial growth factor (VEGF). Angiogenesis appears to be an important feature of this disease, and recent experimental studies have demonstrated the role of VEGF and its receptors in the pathogenesis of KS. Thus, therapeutic agents that target the VEGF pathway may be an effective strategy in reducing the tumor growth and edema associated with KS. Phase I study results with SU5416, a synthetic low molecular-weight inhibitor of the VEGF-Flk-1/KDR receptor tyrosine kinase, demonstrate that this agent is well tolerated. Preliminary results show that in a majority of patients with autoimmune deficiency syndrome (AIDS)-related disease, SU5416 clearly has biological activity (it flattens, shrinks, or dissolves lesions and reduces or resolves edema) or stabilizes the disease. Angiogenesis inhibition with SU5416 is a promising therapeutic approach in treating patients with KS, and further clinical evaluation is currently under way.
- 27 April 1999
- Vol. 4 (4) , 131-4
Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
Pneumocystis carinii pneumonia (PCP) is one of the most common AIDS defining diagnoses. In a prospective observational trial all cases of Pneumocystis carinii pneumonia (PCP) were evaluated. Patients with and without PCP-prophylaxis were compared for symptoms, efficacy, side effects and mortality at week 4 and 26. 293 patients developed a PCP episode. Patients with no prophylaxis had a significant lower CD4 cell count and a more severe clinical status at time of diagnosis. This was pronounced in the group with first positive HIV test at time of diagnosis. There was no difference in the rate of successful treatment between both groups. At week four a tendency to a better survival in the group with prophylaxis was observed, however this changed to a trend to a better survival at week 26 for the group without prophylaxis. Even in the era of highly active antiretroviral treatment many patients present with PCP. Nearly 60% of patients presented without antiretroviral treatment or PCP-prophylaxis. Nearly 25% of all patients had their first HIV-test at time of PCP diagnosis.
- 27 April 1999
- Vol. 4 (4) , 131-4
Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing antiretroviral therapy - IDKF 13 -. German AIDS Study Group (GASG/IdKF).
Pneumocystis carinii pneumonia (PCP) is one of the most common AIDS defining diagnoses. In a prospective observational trial all cases of Pneumocystis carinii pneumonia (PCP) were evaluated. Patients with and without PCP-prophylaxis were compared for symptoms, efficacy, side effects and mortality at week 4 and 26. 293 patients developed a PCP episode. Patients with no prophylaxis had a significant lower CD4 cell count and a more severe clinical status at time of diagnosis. This was pronounced in the group with first positive HIV test at time of diagnosis. There was no difference in the rate of successful treatment between both groups. At week four a tendency to a better survival in the group with prophylaxis was observed, however this changed to a trend to a better survival at week 26 for the group without prophylaxis. Even in the era of highly active antiretroviral treatment many patients present with PCP. Nearly 60% of patients presented without antiretroviral treatment or PCP-prophylaxis. Nearly 25% of all patients had their first HIV-test at time of PCP diagnosis.
- 16 December 1998
- Vol. 3 (12) , 559-63
Sensitivity and specificity of indirect immunofluorescence and Grocott-technique in comparison with immunocytology (alkaline phosphatase anti alkaline phosphatase = APAAP) for the diagnosis of Pneumocystis carinii in broncho-alveolar lavage (BAL).
The purpose of the study was to compare the sensitivity and specificity of the indirect method of immunofluorescence with the immunocytological technique of alkaline phosphatase anti alkaline phosphatase complex (APAAP) for the detection of Pneumocystis carinii by bronchoalveolar lavage (BAL) in HIV-1 positive patients. - 83 HIV-1 positive patients with clinical presentations suggestive of Pneumocystis carinii pneumonia (PcP) were included in the study. 28 samples were found Pc-positive by immunofluorescence (IFT), 26 by Grocott and 29 by APAAP. In comparison to the lab results 33 patients were diagnosed as PcP according to the clinical course (i.e. therapeutic outcome, drugs used, and therapy changes). Compared to the clinical diagnoses, the following lab tests proved to be false positive and false negative: false positive: IF = 1, Grocott = 0, APAAP = 4 (3F6). false negative: IF = 5, Grocott = 7, APAAP = 4 (3F6). - Grocott stain shows insufficient correlation to the clinical diagnoses (p = 0.0156, McNemar-Test, two-tailed). - The two different detection methods (IFT and APAAP) showed no significant statistical difference with regard to their sensitivity (p = 0.3438, McNemar-Test, two tailed) and specificity. Considering cost and time the immunofluorescence technique seems to be the most suitable for the diagnosis of PcP in HIV-1 positive patients.
- 16 December 1998
- Vol. 3 (12) , 559-63
Sensitivity and specificity of indirect immunofluorescence and Grocott-technique in comparison with immunocytology (alkaline phosphatase anti alkaline phosphatase = APAAP) for the diagnosis of Pneumocystis carinii in broncho-alveolar lavage (BAL).
The purpose of the study was to compare the sensitivity and specificity of the indirect method of immunofluorescence with the immunocytological technique of alkaline phosphatase anti alkaline phosphatase complex (APAAP) for the detection of Pneumocystis carinii by bronchoalveolar lavage (BAL) in HIV-1 positive patients. - 83 HIV-1 positive patients with clinical presentations suggestive of Pneumocystis carinii pneumonia (PcP) were included in the study. 28 samples were found Pc-positive by immunofluorescence (IFT), 26 by Grocott and 29 by APAAP. In comparison to the lab results 33 patients were diagnosed as PcP according to the clinical course (i.e. therapeutic outcome, drugs used, and therapy changes). Compared to the clinical diagnoses, the following lab tests proved to be false positive and false negative: false positive: IF = 1, Grocott = 0, APAAP = 4 (3F6). false negative: IF = 5, Grocott = 7, APAAP = 4 (3F6). - Grocott stain shows insufficient correlation to the clinical diagnoses (p = 0.0156, McNemar-Test, two-tailed). - The two different detection methods (IFT and APAAP) showed no significant statistical difference with regard to their sensitivity (p = 0.3438, McNemar-Test, two tailed) and specificity. Considering cost and time the immunofluorescence technique seems to be the most suitable for the diagnosis of PcP in HIV-1 positive patients.
- 1 December 1997
- Published by Springer Nature in Mycopathologia
- Vol. 140 (3) , 115-120
Co-infection by Cryptococcus neoformans and Mycobacterium aKeikawusvium intracellulare in AIDS
In the observation of various opportunistic pathogens in HIV-positive persons, co-infection by Cryptococcus neoformans together with Mycobacterium avium intracellulare was found if there was a CD4...
- 1 December 1997
- Published by Springer Nature in Mycopathologia
- Vol. 140 (3) , 115-120
Co-infection by Cryptococcus neoformans and Mycobacterium aKeikawusvium intracellulare in AIDS
In the observation of various opportunistic pathogens in HIV-positive persons, co-infection by Cryptococcus neoformans together with Mycobacterium avium intracellulare was found if there was a CD4...